JACOBS LEVY EQUITY MANAGEMENT, INC - ARBUTUS BIOPHARMA CORP ownership

ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 114 filers reported holding ARBUTUS BIOPHARMA CORP in Q4 2022. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.

Quarter-by-quarter ownership
JACOBS LEVY EQUITY MANAGEMENT, INC ownership history of ARBUTUS BIOPHARMA CORP
ValueSharesWeighting
Q3 2022$351,000
+111.4%
183,867
+230.0%
0.00%
+200.0%
Q1 2022$166,000
-23.5%
55,7130.0%0.00%0.0%
Q4 2021$217,000
+239.1%
55,713
+82.1%
0.00%0.0%
Q2 2019$64,000
-17.9%
30,593
+40.4%
0.00%0.0%
Q1 2019$78,00021,7960.00%
Other shareholders
ARBUTUS BIOPHARMA CORP shareholders Q4 2022
NameSharesValueWeighting ↓
Foresite Capital Management IV, LLC 3,705,128$10,300,0004.44%
RTW INVESTMENTS, LP 5,666,754$15,754,0000.59%
COWEN AND COMPANY, LLC 926,200$2,575,0000.22%
Hudson Bay Capital Management LP 850,000$2,363,0000.05%
LADENBURG THALMANN FINANCIAL SERVICES INC. 1,774,915$4,934,0000.03%
Point72 Asset Management, L.P. 1,897,284$5,274,0000.03%
683 Capital Management, LLC 77,368$215,0000.02%
Secure Asset Management, LLC 10,000$28,0000.02%
Qube Research & Technologies Ltd 166,138$462,0000.01%
Verition Fund Management LLC 174,455$485,0000.01%
View complete list of ARBUTUS BIOPHARMA CORP shareholders